HOME > Outline of Japan Atherosclerosis Society >Message from the President
Outline of Japan Atherosclerosis Society
Message from the President
President, Japan Atherosclerosis Society  Ken-ichi Hirata
President, Japan Atherosclerosis Society
Ken-ichi Hirata

I am Ken-ichi Hirata from Kobe University. It is my great honor to be appointed as the 11th president of the Japan Atherosclerosis Society (JAS) succeeding the past president Dr. Shizuya Yamashita, the director of Rinku General Medical Center, who has completed his term of office. With 50 years of its history, JAS has 2,433 active members as of April 1st, 2019. Besides my privilege, I also feel a deep sense of responsibility in undertaking the role.

The average lifespan in Japan ranks second in the world, and our society is often described as ’super-aging.’ However, there is a great difference between the average lifespan and the healthy lifespan, and the prevention of atherosclerotic disease is the most critical issue for extending the healthy lifespan. JAS has made significant contributions to the prevention, diagnosis, and treatment of atherosclerotic cardiovascular diseases, including the publication of the “Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases” and “Diagnostic Criteria for Metabolic Syndrome”. Facing super-aging society in Japan, the role and the responsibility of JAS is growing larger and larger.

Basic research and clinical research were inseparable in the development of the field of atherosclerosis. Traditionally, we have emerged and evolved focusing on pathology, dyslipidemia and vascular biology, and creative researches have been conducted. In clinical research, important clinical trials and epidemiological studies on coronary artery disease, cerebrovascular disease, and peripheral artery disease have been performed. We have been able to compile a great deal of evidence for treatments to lower LDL cholesterol (LDL-C) levels, and to make great contributions to the publication and dissemination of “JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases”. In addition to the reduction of LDL-C, interventions in other risks such as metabolic syndrome and diabetes are important to reduce atherosclerotic diseases. It is also necessary to accumulate evidence in Asia, and it is crucial for us to play a central role in activating atherosclerosis research in the Asian countries in cooperation with the International Atherosclerosis Society (IAS), the European Atherosclerosis Society (EAS), and the Asian-Pacific Society of Atherosclerosis and Vascular Disease (APSAVD).

Our society has been publishing the Journal of Atherosclerosis and Thrombosis (JAT) as our official scientific journal and has been providing the latest and scientific information on arteriosclerosis. Recently, more than 400 papers are submitted every year, and the Impact Factor increased to 3.478 in 2018. We continue to aim for further development of JAT as a reputable international academic journal.

Research on atherosclerosis made significant progress in the 20th century. Intervention for atherosclerotic diseases by medical team is required to achieve further progress in this field. We would like to provide places and occasions where doctors who are interested in atherosclerosis as well as also other professionals such as nurses, dietitians, and clinical laboratory technicians. By gathering the power of the younger generation in our society, further prevention of atherosclerosis can be achieved by expanding our activities from multi-angle viewpoints.

In the next two years, I will devote my greatest effort on these issues, and contribute to the development of the JAS. Your continued support would be sincerely and greatly appreciated.


Respectfully,



April 2020
Ken-ichi Hirata, MD, PhD
President of the Japan Atherosclerosis Society
(Graduate School of Medicine, Kobe University)